Table 14.5.4: Lab Shift Table Safety Population

| | Post-Baseline Reference Range | | | |
|--------------------|-------------------------------|------------|----------|------------|
| Lab Test | | | | |
| Visit | | | | |
| Treatment | Low | Normal | High | Total |
| Baseline Range | n (%) | n (%) | n (%) | n (%) |
| Albumin, Total | | | | 51 |
| Week 1, Total | | | | 51 |
| Placebo, Total | 0 | 18 (100.0) | 0 | 18 |
| Low | 0 | 1 (5.6) | 0 | 1 (5.6) |
| Normal | 0 | 16 (88.9) | 0 | 16 (88.9) |
| High | 0 | 1 (5.6) | 0 | 1 (5.6) |
| Treatment A, Total | 1 (6.7) | 12 (80.0) | 2 (13.3) | 15 |
| Low | 0 | 0 | 0 | 0 |
| Normal | 1 (6.7) | 12 (80.0) | 2 (13.3) | 15 (100.0) |
| High | 0 | 0 | 0 | 0 |
| Treatment B, Total | 2 (11.1) | 15 (83.3) | 1 (5.6) | 18 |
| Low | 0 | 0 | 0 | 0 |
| Normal | 2 (11.1) | 15 (83.3) | 1 (5.6) | 18 (100.0) |
| High | 0 | 0 | 0 | 0 |

Nimble Clinical Research Drug Name: Nimort-01

Table 14.5.4: Lab Shift Table Safety Population

| | Post-Baseline Reference Range | | | |
|--------------------------------|-------------------------------|-----------------|---------------|----------------|
| ab Test | | | | |
| Visit Treatment Baseline Range | Low n (%) | Normal n (%) | High n (%) | Total n (%) |
| Week 2, Total | | | | 43 |
| Placebo, Total | 2 (13.3) | 13 (86.7) | 0 | 15 |
| Low | 0 | 1 (6.7) | 0 | 1 (6.7) |
| Normal | 2 (13.3) | 11 (73.3) | 0 | 13 (86.7) |
| High | 0 | 1 (6.7) | 0 | 1 (6.7) |
| Treatment A, Total | 2 (15.4) | 10 (76.9) | 1 (7.7) | 13 |
| Low | 0 | 0 | 0 | 0 |
| Normal | 2 (15.4) | 10 (76.9) | 1 (7.7) | 13 (100.0) |
| High | 0 | 0 | 0 | 0 |
| Treatment B, Total | 1 (6.7) | 14 (93.3) | 0 | 15 |
| Low | 0 | 0 | 0 | 0 |
| Normal | 1 (6.7) | 14 (93.3) | 0 | 15 (100.0) |
| High | 0 | 0 | 0 | 0 |

Table 14.5.4: Lab Shift Table Safety Population

| | Post-Baseline Reference Range | | | |
|--------------------|-------------------------------|------------|-------|------------|
| _ab Test | | | | |
| Visit | | | | |
| Treatment | Low | Normal | High | Total |
| Baseline Range | n (%) | n (%) | n (%) | n (%) |
| Chloride, Total | | | | 51 |
| Week 1, Total | | | | 51 |
| Placebo, Total | 0 | 18 (100.0) | 0 | 18 |
| Low | 0 | 0 | 0 | 0 |
| Normal | 0 | 18 (100.0) | 0 | 18 (100.0) |
| High | 0 | 0 | 0 | 0 |
| Treatment A, Total | 0 | 15 (100.0) | 0 | 15 |
| Low | 0 | 1 (6.7) | 0 | 1 (6.7) |
| Normal | 0 | 14 (93.3) | 0 | 14 (93.3) |
| High | 0 | 0 | 0 | 0 |
| Treatment B, Total | 0 | 18 (100.0) | 0 | 18 |
| Low | 0 | 0 | 0 | 0 |
| Normal | 0 | 18 (100.0) | 0 | 18 (100.0) |
| High | 0 | 0 | 0 | 0 |

Table 14.5.4: Lab Shift Table Safety Population

| | Post-Baseline Reference Range | | | |
|--------------------|-------------------------------|------------|-------|------------|
| ab Test | | | | |
| Visit | | | | |
| Treatment | Low | Normal | High | Total |
| Baseline Range | n (%) | n (%) | n (%) | n (%) |
| Week 2, Total | | | | 43 |
| Placebo, Total | 0 | 15 (100.0) | 0 | 15 |
| Low | 0 | 0 | 0 | 0 |
| Normal | 0 | 15 (100.0) | 0 | 15 (100.0) |
| High | 0 | 0 | 0 | 0 |
| Treatment A, Total | 0 | 13 (100.0) | 0 | 13 |
| Low | 0 | 1 (7.7) | 0 | 1 (7.7) |
| Normal | 0 | 12 (92.3) | 0 | 12 (92.3) |
| High | 0 | 0 | 0 | 0 |
| Treatment B, Total | 0 | 15 (100.0) | 0 | 15 |
| Low | 0 | 0 | 0 | 0 |
| Normal | 0 | 15 (100.0) | 0 | 15 (100.0) |
| High | 0 | 0 | 0 | 0 |

Table 14.5.4: Lab Shift Table Safety Population

| | Post-Baseline Reference Range | | | |
|--------------------|-------------------------------|------------|-------|------------|
| Lab Test | | | | |
| Visit | | | | |
| Treatment | Low | Normal | High | Total |
| Baseline Range | n (%) | n (%) | n (%) | n (%) |
| Potassium, Total | | | | 51 |
| Week 1, Total | | | | 51 |
| Placebo, Total | 0 | 18 (100.0) | 0 | 18 |
| Low | 0 | 0 | 0 | 0 |
| Normal | 0 | 18 (100.0) | 0 | 18 (100.0) |
| High | 0 | 0 | 0 | 0 |
| Treatment A, Total | 0 | 15 (100.0) | 0 | 15 |
| Low | 0 | 0 | 0 | 0 |
| Normal | 0 | 14 (93.3) | 0 | 14 (93.3) |
| High | 0 | 1 (6.7) | 0 | 1 (6.7) |
| Treatment B, Total | 0 | 18 (100.0) | 0 | 18 |
| Low | 0 | 0 | 0 | 0 |
| Normal | 0 | 18 (100.0) | 0 | 18 (100.0) |
| High | 0 | 0 | 0 | 0 |

Table 14.5.4: Lab Shift Table Safety Population

| | Post-Baseline Reference Range | | | |
|--------------------|-------------------------------|------------|----------|------------|
| ab Test | | | | |
| Visit | | | | |
| Treatment | Low | Normal | High | Total |
| Baseline Range | n (%) | n (%) | n (%) | n (%) |
| Week 2, Total | | | | 43 |
| Placebo, Total | 0 | 12 (80.0) | 3 (20.0) | 15 |
| Low | 0 | 0 | 0 | 0 |
| Normal | 0 | 12 (80.0) | 3 (20.0) | 15 (100.0) |
| High | 0 | 0 | 0 | 0 |
| Treatment A, Total | 0 | 13 (100.0) | 0 | 13 |
| Low | 0 | 0 | 0 | 0 |
| Normal | 0 | 12 (92.3) | 0 | 12 (92.3) |
| High | 0 | 1 (7.7) | 0 | 1 (7.7) |
| Treatment B, Total | 0 | 14 (93.3) | 1 (6.7) | 15 |
| Low | 0 | 0 | 0 | 0 |
| Normal | 0 | 14 (93.3) | 1 (6.7) | 15 (100.0) |
| High | 0 | 0 | 0 | 0 |